

Coupling Mass Spectrometry (MS) with non-MS Assays for Automated Profiling of Antibody Impurities


Harsha Gunawardena

CASSS WCBP Conference 2025


Outline

- Need for speed and comprehensive characterization in pharmaceutical R&D
- **Part 1: Proposed peak identification strategy: concepts and experiments**
 - Non-MS-assays and peak detection a historical perspective
 - Developing mass/size calibration ruler: A case for forced trisulfide degradation products (that mimic bioreactor H₂S-induced mAb degradation)
 - Cathepsin D- and L-induced mAb clipping to mimic cell culture harvest conditions
 - High-pH Rituximab clipping to mimic structural instability under forced degradation
- **Part 2: MS and non-MS Data Automation to couple Byosphere**
 - Coupling RapidFire data with non-MS assays
 - Data analysis in the Byosphere pipeline
 - Automated analysis and reporting of Impurities
- Conclusions and Future directions

Multispecific Modalities Requires Faster and Comprehensive Characterization Workflows in Drug Discovery & Development



Analytical Assays Automation with Rapid Informatics Pipeline




1. LIMS system supports the retrieval of samples
2. Automated protein A purification using robotics and robotic hand-off (Future state)
3. Non-MS Assays (i.e. Proteometer Trace Chromatograms)
4. Data servers storing data
5. Automated data sweep to *Enterprise Byos Software* with fully integrated intact MS Data-driven workflows
6. Automated export of results and joint reporting of modifications
- 7&8 Aggregate data with molecule information to build 'In-house' knowledge base (also auto QC)

Outline

- Need for speed and comprehensive characterization in pharmaceutical R&D
- **Part 1: Proposed peak identification strategy: concepts and experiments**
 - Non-MS assays and peak detection a historical perspective
 - Developing mass/size calibration ruler: A case for forced trisulfide degradation products (that mimic bioreactor H₂S-induced mAb degradation)
 - Cathepsin D- and L-induced mAb clipping to mimic cell culture harvest conditions
 - High-pH Rituximab clipping to mimic structural instability under forced degradation
- Part 2: MS and non-MS Data Automation to couple Byosphere
 - Coupling RapidFire data with non-MS assays
 - Data analysis in the Byosphere pipeline
 - Automated analysis and reporting of Impurities
- Conclusions and Future directions

The problem: peak detection of non-MS Assays



CE-SDS (UV 220 nm)



Chip-Electrophoresis



CZE, HPLC



Estimating Molecular Weight by Mobility Calibration

scientific reports

www.nature.com/scientificreports




hgunawar@its.jnj.com

Check for updates

OPEN


Rapid identification of antibody impurities in size-based electrophoresis via CZE-MS generated spectral library

Quan Liu^{2,4}, Jiaying Hong^{2,4}, Yukun Zhang², Qiuyue Wang², Qiangwei Xia², Michael D. Knierman³, Jim Lau³, Caleen Dayaratna¹, Benjamin Negrón¹, Hirsh Nanda¹ & Harsha P. Gunawardena¹✉



- Molecular weight of proteins estimated by calibrating mobility with mass from SDS-PAGE (Zwan. 1966, ***Anal. Biochem.***)
- Molecular weight of IgG clipping estimated by calibrating mobility with mass from CE-MS (Li et al., 2022, ***J. Chromatography A.***)
- Molecular weight of unknown IgG impurities estimated by calibrating mobility using mass spectral library (Liu et al., 2023, ***Scientific Reports***)) **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>.

A workflow for mAb impurity analysis combining electrophoretic separation and accurate assignment of masses




Simulating Bioprocessing Systems to Examine mAb Impurities




mAb Trisulfides and degradation in bioreactor settings

Monitoring NIST mAb H2S-Induced degradation products by GXII and CZE-MS



mAb Cathepsin degradation during cell culture



Monitoring NIST mAb Cathepsin degradation products by GXII and CZE-MS



mAb High-pH degradation during bioprocessing

Monitoring Rituximab high-pH degradation products by GXII and CZE-MS

H₂S-induced degradation products of IgG as a GXII mobility ruler




Analysis of degradation products of NISTmAb
A) LabChip GXII electropherogram of unknown mAb fragments peak 1-5 under unstressed (native condition).

B) Deconvoluted mass spectrum resulting from H₂S-induced degradation products of NISTmAb.

C) Linear regression analysis via NISTmAb fragments.






D) Assignment of masses to GXII peaks based on calibration in C

GXII Electropherogram Analysis of NIST IgG1 Fragments




- x-axis time variance is important for the accuracy of size (kDa) estimation (Peak ID)
- Each second in GXII time is ~ 15 KDa in size
- GXII Calibration of higher masses is an extrapolation of low molecular weight markers


CZE-MS of NIST H₂S-Induced Degradation Products




GXII Electropherogram Analysis of NIST IgG1 Fragments



Peak Identification Strategy



Plot Mobility versus log10 of Molecular Weight (MW)




Simulating Bioprocessing Systems to Examine mAb Impurities




mAb Trisulfides and degradation in bioreactor settings

Monitoring NIST mAb H_2S -Induced degradation products by GXII and CZE-MS



mAb Cathepsin degradation during cell culture


Monitoring NIST mAb Cathepsin degradation products by GXII and CZE-MS





mAb High-pH degradation during bioprocessing

Monitoring Rituximab high-pH degradation products by GXII and CZE-MS

Overlaid GXII-FLR Traces of Cathepsin D and L at Day 1 and Day2




Cathepsin-D and -L Cleavages of Light Chain




NIST IgG1



Peak Identification of Cathepsin-D, and -L Fragments




Unassigned Peaks in Cathepsin-D and -L Fragments




Minimization of Time Errors: An approach to increase Peak ID's




Assigning Unassigned Peaks in Cathepsin-D and -L Fragments





pH3 Cathepsin L-Induced NIST IgG1 Light Chain AA and FI Clips





Cathepsin L Cleavage Sites
CDR-L1, CDR-L2, CDR-L3 of LC



pH3 Cathepsin L CZE-MS Identification of Clips





pH3 Cathepsin L CZE-MS Deconvolution Mass of AA and FI Clips





- MS1 Peak IDs of AA and FI Clip

pH7 Cathepsin L CZE-MS Exclusively Shows Light Chain FI Clip





- Unambiguous MS2 Sequence Confirmation of FI Clip by CE-MS/MS


pH3 Cathepsin L CZE-MS/MS of Light Chain AA Clip




pH3 Cathepsin L CZE-MS Identification FL Clip



Peak Assignment of pH3 Cathepsin L CZE-MS Identification FL Clip




pH3 Cathepsin L-Induced 47.6 Da, HT Clips






1 = LC and 2 = Fd'

CDR-L1, CDR-L2, CDR-L3 of LC

CDR-H1, CDR-H2, CDR-H3 of HC




pH3 Cathepsin L CZE-MS of 47.6 kDa, Fragment due to HT Clip






Heavy Chain (H) Assignment is truly a Fab' generated via two HT Clips


Reassignment of Misidentified peaks 47.6 kDa, Fragment HT Clip






pH 5 Cathepsin D, CZE-MS Unidentified Peaks



Reassignment of Misidentified peaks 18 kDa, Fragment Pair





pH7 Cathepsin L CZE-MS of 105.9 kDa Fragment




(HH) Assignment is a mAb with truncated light chains via two SS Clips


Reassignment of Peak ID's via Minimization of Time Errors




Reassignment of Misidentified peaks Light Chain SS Clips



Overlaid GXII-FLR Traces of Cathepsin D and L Impurities




Simulating Bioprocessing Systems to Examine mAb Impurities




mAb Trisulfides and degradation in bioreactor settings

Monitoring NIST mAb H₂S-Induced degradation products by GXII and CZE-MS



mAb Cathepsin degradation during cell culture


Monitoring NIST mAb Cathepsin degradation products by GXII and CZE-MS



mAb High-pH degradation during bioprocessing


Monitoring Rituximab high-pH degradation products by GXII and CZE-MS

pH 10 Ammonia-Induced Rituximab Light Chain Clip




Rituximab Light Chain:

QIVLSQSPAILSASPGEKVTMTCRASSVSYIHWFFQQKPGSSPKPWIYA
TSNLASGVPPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFG
GGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYFPREAKVQW
KVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVT
HQGLSPVTKSFNRGEC




Rituximab Light Chain has a NPP motif that is susceptible to NP-cleavage at high pH

Overlaid GXII-FLR Traces of Rituximab pH-Induced Forced Degradation




Identification of Rituximab pH-Induced Degradation Products



Agilent ExD cell for 6545XT AdvanceBio LC/Q-TOF

- Key Features



Simplified Operation




Enhanced ECD Efficiency



Synergy with 6545XT




ExDViewer Software



Enhanced ECD Efficiency



- ✓ Greater confidence in results
- ✓ Less time spent fine-tuning
- ✓ Greater applicability for:
 - Lower-abundance/impurities
 - Lower-charge cations
 - Difficult analytes




Outline


- Need for speed and comprehensive characterization in pharmaceutical R&D
- Part 1: **Proposed peak identification strategy: concepts and experiments**
 - Non-MS assays and peak detection a historical perspective
 - Developing mass/size calibration ruler: A case for forced trisulfide degradation products (that mimic bioreactor H₂S-induced mAb degradation)
 - Cathepsin D- and L-induced mAb clipping to mimic cell culture harvest conditions
 - High-pH Rituximab clipping to mimic structural instability under forced degradation
- **Part 2: MS and non-MS Data Automation to couple Byosphere**
 - Coupling RapidFire data with non-MS assays
 - Data analysis in the Byosphere pipeline
 - Automated analysis and reporting of Impurities
- Conclusions and Future directions

High-throughput MS data generation via RpidFire 360-6545XT Q/TOF

A



B



A) 96-well plate of bsAb subjected intact MS analysis via RapidFire-MS, spectral deconvolution and data visualization as Byos plate report


B) Representative RAW mass spectrum and corresponding deconvoluted mass spectrum

Byosphere Traffic Light Reports to Examine RapidFire Plates


Color Legend: Pass; Review; Failed

		PlateCols	1	2	3	4	5	6	7	8	9	10	11	12
Plate Barcode ↑	Plate Rows ↑													
L0000007315	A		1		2	2	2	2	2	2	2		2	2
	B		1		2	2	2	2	2	2	1	2	2	2
	C		1		2	2	2	1	1	2	1	2	2	2
	D		1		2	2	1	2	2	2	1	2	2	2
	E		1		2	2		2	1	2	1	2	1	2
	F				2	1	1	2	1	2	1	2	2	2
	G			1	2	2	1	1	1	2		2	2	2
	H			2	2		1	2	2	2		2	1	1

- 96-well plate report for easy visualization of sample wells
- Reports annotated with plate barcodes
- Traffic lights to triage molecules based on identification





Byosphere Assay Automation of Non-MS with MS





- Byosphere pipeline process both MS and non-MS data (i.e., GXII)
- Workflow processes MS and non-MS workflows and creates projects
- A hands-free automated report generation
- Deep querying capabilities with metadata fields
- Dashboards to monitor QC data

Future Directions: Software Automation for GXII Peak Annotation

Fast MS (RapidFire-MS)



Fast Electropherogram (i.e., GXII)



Conclusions and Future Directions

- We successfully demonstrate a radical approach to obtain accurate peak identifications for size-based electrophoresis.
- We show the approach and its utility by applying to biopharmaceutical impurities.
- CZE-MS identifications greatly enhance GXII peaks assignment.
- We are currently exploring the integration RapidFire-MS for peak identification of non-MS assays we automated comprehensive impurity library generation.
- We envision that software automation will enable seamless peak identification of non-MS assays.
- Potential to add Alternative Fragmentation ECD - faster ID of unknowns.
- Consider a similar approach with downstream Development - enhance MW accuracy and ID of impurities in QC, updating calibration curves in QC.

Acknowledgements

Biophysics Separations Team

- **Caleen Dayaratna**
- **Ben Negron**
- Kristen Nields
- Megan Sharma
- Bob Hepler

MS Characterization Team

- Partha Chowdhury
- Hirsh Nanda
- Elsa Gorre
- Andrew Mahan
- Achutha Madhankumar
- Michael Poltash
- Chris Sauer
- Weija Tang
- Tacora Yeargins
- Bo Zhai
- Eric Beil



- Gihoon Lee
- Joshua Justice
- Javier Gomez

Discovery Chemistry

- Mark Wall

J&J
CEAS



Agilent Technologies

- John Sausen
- Jim Lau
- Mike Knierman
- Chris Klein
- Wayne Heacock



CMPScientific

- James Xia
- Quan Liu
- Jiaying Hong
- Yukun Zhang
- Qiuyue Wang



PROTEIN METRICS

- Eric Carlson
- Marshall Bern
- Alex Zhai
- Steve Cypes
- Ilker Sen